drugset / Trial / NCT01546415

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

NCT01546415 ↗

Phase 4 Completed 64 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study is designed to collect safety and efficacy of Desferasirox in Chinese patients with Iron Overload and Aplastic Anemia.

Timeline

Start
2011-10
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Desferasirox Unknown 20 mg/kg —